Predictors of progression in systemic sclerosis patients with interstitial lung disease Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019 Year: 2020
Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis Source: Eur Respir J 2014; 43: 1530-1532 Year: 2014
IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019
CCL18 as marker of disease progression in systemic sclerosis Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003
The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008
Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis Source: Eur Respir J 2009; 34: 1376-1382 Year: 2009
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020
Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013
Disease course and outcome of progressive interstitial lung disease in systemic sclerosis Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019
Auto-antibody subsets and extent of pulmonary fibrosis in systemic sclerosis (SSc) Source: Eur Respir J 2005; 26: Suppl. 49, 202s Year: 2005
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017 Year: 2018
Immunosuppression for interstitial lung disease in systemic sclerosis}, Source: Eur Respir Rev 2013; 22: 236-243 Year: 2013
Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020
Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013
Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin Source: Eur Respir J 2001; 18: 17S-29S Year: 2001
Clinical characteristics of interstitial lung fibrosis in progressive systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 95s Year: 2006
Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease Source: Eur Respir J, 53 (5) 1802182; 10.1183/13993003.02182-2018 Year: 2019